Search

everythinglearnresearchcommunity

for

Search:↓

No consistent link between genotype and phenotype in 5-α-Reductase type 2 deficiency.

Three siblings with a rare genetic condition had abnormal sexual development and chose different gender identities, needing surgery and therapy.

The document concludes that managing non-classical congenital adrenal hyperplasia in females requires personalized treatment, genetic counseling, and a team of specialists.

Using finasteride or dutasteride may cause long-lasting erectile dysfunction.

Women with congenital adrenal hyperplasia have lower fertility, but with proper treatment, they can conceive successfully.

Late diagnosis of congenital adrenal hyperplasia can greatly affect physical development, gender identity, and sexual health.

Finasteride and spironolactone both reduce hirsutism, but finasteride lowers androgen levels more.

Spironolactone harms fish reproduction and is more potent in fish than invertebrates, needing environmental monitoring.

Mouse genital development depends on male or female hormones for specific features.

Finasteride exposure affects gene expression and anogenital distance in male rat fetuses.

Androgen treatment with dihydrotestosterone may help maintain height in patients with 5-α-reductase type 2 deficiency, especially before puberty.

Hyperandrogenism is a common hormonal disorder in women, often linked to PCOS.

A woman's masculine symptoms were caused by an ovarian tumor, which improved after surgery.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

PGD2 stops hair growth and is higher in bald men with AGA.

Most women with excess hair growth have an underlying hormonal issue, often treated with medication and hair removal methods.

Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.

The document concludes that proper diagnosis and a multidisciplinary approach are crucial for managing Congenital Adrenal Hyperplasia effectively.

The document concludes that early diagnosis and treatment of Congenital Adrenal Hyperplasia are crucial for preventing serious health issues and improving patient outcomes.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

New treatments for male hypogonadism are effective and should be personalized.

Androgens cause skin issues like acne and hair growth in women, often due to PCOS, and can be treated with medication and lifestyle changes.

The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Women with polycystic ovary syndrome tend to have a longer anogenital distance.